These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 22995073)

  • 1. Enabling structure-based drug design of Tyk2 through co-crystallization with a stabilizing aminoindazole inhibitor.
    Argiriadi MA; Goedken ER; Banach D; Borhani DW; Burchat A; Dixon RW; Marcotte D; Overmeyer G; Pivorunas V; Sadhukhan R; Sousa S; Moore NS; Tomlinson M; Voss J; Wang L; Wishart N; Woller K; Talanian RV
    BMC Struct Biol; 2012 Sep; 12():22. PubMed ID: 22995073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rational mutagenesis to support structure-based drug design: MAPKAP kinase 2 as a case study.
    Argiriadi MA; Sousa S; Banach D; Marcotte D; Xiang T; Tomlinson MJ; Demers M; Harris C; Kwak S; Hardman J; Pietras M; Quinn L; DiMauro J; Ni B; Mankovich J; Borhani DW; Talanian RV; Sadhukhan R
    BMC Struct Biol; 2009 Mar; 9():16. PubMed ID: 19296855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2).
    Min X; Ungureanu D; Maxwell S; Hammarén H; Thibault S; Hillert EK; Ayres M; Greenfield B; Eksterowicz J; Gabel C; Walker N; Silvennoinen O; Wang Z
    J Biol Chem; 2015 Nov; 290(45):27261-27270. PubMed ID: 26359499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-Based Design and Synthesis of 3-Amino-1,5-dihydro-4H-pyrazolopyridin-4-one Derivatives as Tyrosine Kinase 2 Inhibitors.
    Yogo T; Nagamiya H; Seto M; Sasaki S; Shih-Chung H; Ohba Y; Tokunaga N; Lee GN; Rhim CY; Yoon CH; Cho SY; Skene R; Yamamoto S; Satou Y; Kuno M; Miyazaki T; Nakagawa H; Okabe A; Marui S; Aso K; Yoshida M
    J Med Chem; 2016 Jan; 59(2):733-49. PubMed ID: 26701356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2.
    Liu C; Lin J; Langevine C; Smith D; Li J; Tokarski JS; Khan J; Ruzanov M; Strnad J; Zupa-Fernandez A; Cheng L; Gillooly KM; Shuster D; Zhang Y; Thankappan A; McIntyre KW; Chaudhry C; Elzinga PA; Chiney M; Chimalakonda A; Lombardo LJ; Macor JE; Carter PH; Burke JR; Weinstein DS
    J Med Chem; 2021 Jan; 64(1):677-694. PubMed ID: 33370104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of a peptide inhibitor of tyrosine kinase 2.
    Works MG; Song B; Kibler P; Tanga MJ; Galande AK; D'Andrea A
    Protein Pept Lett; 2014 May; 21(5):419-25. PubMed ID: 24304386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Demonstration of In Vitro to In Vivo Translation of a TYK2 Inhibitor That Shows Cross Species Potency Differences.
    Gerstenberger BS; Banker ME; Clark JD; Dowty ME; Fensome A; Gifford R; Griffor MC; Hegen M; Hollingshead BD; Knafels JD; Lin TH; Smith JF; Vajdos FF
    Sci Rep; 2020 Jun; 10(1):8974. PubMed ID: 32488071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases.
    Gerstenberger BS; Ambler C; Arnold EP; Banker ME; Brown MF; Clark JD; Dermenci A; Dowty ME; Fensome A; Fish S; Hayward MM; Hegen M; Hollingshead BD; Knafels JD; Lin DW; Lin TH; Owen DR; Saiah E; Sharma R; Vajdos FF; Xing L; Yang X; Yang X; Wright SW
    J Med Chem; 2020 Nov; 63(22):13561-13577. PubMed ID: 32787094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of selective TYK2 inhibitors: Design, synthesis, in vitro and in silico studies of promising hits with triazolopyrimidinone scaffold.
    Istanbullu H; Coban G; Turunc E; Disel C; Debelec Butuner B
    Bioorg Chem; 2024 Jul; 148():107430. PubMed ID: 38728909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of Tyk2 inhibitors via the virtual site-directed fragment-based drug design.
    Jang WD; Kim JT; Son HY; Park SY; Cho YS; Koo TS; Lee H; Kang NS
    Bioorg Med Chem Lett; 2015 Sep; 25(18):3947-52. PubMed ID: 26231159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lead identification of novel and selective TYK2 inhibitors.
    Liang J; Tsui V; Van Abbema A; Bao L; Barrett K; Beresini M; Berezhkovskiy L; Blair WS; Chang C; Driscoll J; Eigenbrot C; Ghilardi N; Gibbons P; Halladay J; Johnson A; Kohli PB; Lai Y; Liimatta M; Mantik P; Menghrajani K; Murray J; Sambrone A; Xiao Y; Shia S; Shin Y; Smith J; Sohn S; Stanley M; Ultsch M; Zhang B; Wu LC; Magnuson S
    Eur J Med Chem; 2013 Sep; 67():175-87. PubMed ID: 23867602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1.
    Fensome A; Ambler CM; Arnold E; Banker ME; Clark JD; Dowty ME; Efremov IV; Flick A; Gerstenberger BS; Gifford RS; Gopalsamy A; Hegen M; Jussif J; Limburg DC; Lin TH; Pierce BS; Sharma R; Trujillo JI; Vajdos FF; Vincent F; Wan ZK; Xing L; Yang X; Yang X
    Bioorg Med Chem; 2020 May; 28(10):115481. PubMed ID: 32253095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165.
    Wrobleski ST; Moslin R; Lin S; Zhang Y; Spergel S; Kempson J; Tokarski JS; Strnad J; Zupa-Fernandez A; Cheng L; Shuster D; Gillooly K; Yang X; Heimrich E; McIntyre KW; Chaudhry C; Khan J; Ruzanov M; Tredup J; Mulligan D; Xie D; Sun H; Huang C; D'Arienzo C; Aranibar N; Chiney M; Chimalakonda A; Pitts WJ; Lombardo L; Carter PH; Burke JR; Weinstein DS
    J Med Chem; 2019 Oct; 62(20):8973-8995. PubMed ID: 31318208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a potent and subtype-selective TYK2 degrader based on an allosteric TYK2 inhibitor.
    Kato JY; Korenaga S; Iwakura M
    Bioorg Med Chem Lett; 2023 Jan; 79():129083. PubMed ID: 36414177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, Synthesis and Activity Study of Pyridine Derivatives as Highly Effective and Selective TYK2 Inhibitors.
    Cheng C; Zhou M; Zhang P; Qian W; Chen L; Chen G
    Biomed Res Int; 2022; 2022():6383893. PubMed ID: 35586808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of
    Moslin R; Zhang Y; Wrobleski ST; Lin S; Mertzman M; Spergel S; Tokarski JS; Strnad J; Gillooly K; McIntyre KW; Zupa-Fernandez A; Cheng L; Sun H; Chaudhry C; Huang C; D'Arienzo C; Heimrich E; Yang X; Muckelbauer JK; Chang C; Tredup J; Mulligan D; Xie D; Aranibar N; Chiney M; Burke JR; Lombardo L; Carter PH; Weinstein DS
    J Med Chem; 2019 Oct; 62(20):8953-8972. PubMed ID: 31314518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crystal structure of a polyhistidine-tagged recombinant catalytic subunit of cAMP-dependent protein kinase complexed with the peptide inhibitor PKI(5-24) and adenosine.
    Narayana N; Cox S; Shaltiel S; Taylor SS; Xuong N
    Biochemistry; 1997 Apr; 36(15):4438-48. PubMed ID: 9109651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
    Menichincheri M; Ardini E; Magnaghi P; Avanzi N; Banfi P; Bossi R; Buffa L; Canevari G; Ceriani L; Colombo M; Corti L; Donati D; Fasolini M; Felder E; Fiorelli C; Fiorentini F; Galvani A; Isacchi A; Borgia AL; Marchionni C; Nesi M; Orrenius C; Panzeri A; Pesenti E; Rusconi L; Saccardo MB; Vanotti E; Perrone E; Orsini P
    J Med Chem; 2016 Apr; 59(7):3392-408. PubMed ID: 27003761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6.
    Chrencik JE; Patny A; Leung IK; Korniski B; Emmons TL; Hall T; Weinberg RA; Gormley JA; Williams JM; Day JE; Hirsch JL; Kiefer JR; Leone JW; Fischer HD; Sommers CD; Huang HC; Jacobsen EJ; Tenbrink RE; Tomasselli AG; Benson TE
    J Mol Biol; 2010 Jul; 400(3):413-33. PubMed ID: 20478313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinase crystal identification and ATP-competitive inhibitor screening using the fluorescent ligand SKF86002.
    Parker LJ; Taruya S; Tsuganezawa K; Ogawa N; Mikuni J; Honda K; Tomabechi Y; Handa N; Shirouzu M; Yokoyama S; Tanaka A
    Acta Crystallogr D Biol Crystallogr; 2014 Feb; 70(Pt 2):392-404. PubMed ID: 24531473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.